Amphivena Therapeutics Inc., a newly created subsidiary of venture-backed Affimed Therapeutics AG , has raised $14 million in Series A financing and has granted Janssen Biotech an exclusive option to acquire the company.
Affimed has used its TandAb technology to develop a pipeline of treatments for diseases such as Hodgkin lymphoma and non-Hodgkin lymphoma. Its new subsidiary, Amphivena, will use this technology to address hematologic malignancies, but specifics about its drug program and the indications it will pursue haven't been disclosed....
Funding Rounds (2) - $28MUpdate
Current Team (1)Update
|Jul 17, 2013||Dow Jones Venture Wire - Affimed Subsidiary Amphivena Raises $14M, Signs Deal With Janssen Biotech|
45 JUNIPER STREET
San Francisco, CA 94103